このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Novo Nordisk 将来の成長

Future 基準チェック /36

Novo Nordiskは、15.2%と14.5%でそれぞれ年率15.2%で利益と収益が成長すると予測される一方、EPSはgrowで16.5%年率。

主要情報

15.2%

収益成長率

16.5%

EPS成長率

Pharmaceuticals 収益成長	12.4%
収益成長率	14.5%
将来の株主資本利益率	n/a
アナリストカバレッジ	Good
最終更新日	05 Dec 2023

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

BRSE:NOVOB - アナリストの将来予測と過去の財務データ ( )DKK Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2025	324,306	116,102	100,902	130,030	22
12/31/2024	277,806	98,142	85,610	110,950	23
12/31/2023	229,035	82,638	74,486	100,051	23
9/30/2023	214,490	75,312	77,825	106,458	N/A
6/30/2023	201,325	67,239	67,497	89,731	N/A
3/31/2023	188,290	61,129	67,341	85,115	N/A
12/31/2022	176,954	55,525	64,134	78,887	N/A
9/30/2022	167,195	52,825	57,875	68,769	N/A
6/30/2022	157,251	50,539	57,680	66,037	N/A
3/31/2022	149,027	49,344	59,665	67,331	N/A
12/31/2021	140,800	47,757	47,615	55,000	N/A
9/30/2021	134,605	46,183	40,213	58,189	N/A
6/30/2021	129,910	44,362	31,814	54,188	N/A
3/31/2021	126,875	42,864	31,337	53,194	N/A
12/31/2020	126,946	42,138	29,870	51,951	N/A
9/30/2020	127,225	41,537	44,800	56,944	N/A
6/30/2020	126,575	41,433	47,621	56,126	N/A
3/31/2020	126,605	40,403	36,987	46,904	N/A
12/31/2019	122,021	38,951	35,551	46,782	N/A
9/30/2019	119,336	38,731	36,785	49,029	N/A
6/30/2019	116,821	37,574	31,251	43,960	N/A
3/31/2019	114,192	38,322	32,202	44,691	N/A
12/31/2018	111,831	38,628	32,206	44,616	N/A
9/30/2018	110,091	38,384	31,576	43,236	N/A
6/30/2018	108,943	39,117	33,787	44,538	N/A
3/31/2018	110,174	38,725	28,991	38,885	N/A
12/31/2017	111,696	38,130	32,520	41,168	N/A
9/30/2017	113,276	38,576	38,107	46,289	N/A
6/30/2017	114,199	38,609	N/A	48,557	N/A
3/31/2017	113,020	38,626	N/A	52,937	N/A
12/31/2016	111,780	37,925	N/A	48,314	N/A
9/30/2016	111,084	37,484	N/A	47,280	N/A
6/30/2016	110,339	36,064	N/A	44,179	N/A
3/31/2016	109,939	34,439	N/A	41,656	N/A
12/31/2015	107,927	34,860	N/A	38,287	N/A
9/30/2015	103,636	33,131	N/A	35,469	N/A
6/30/2015	99,093	31,248	N/A	35,578	N/A
3/31/2015	93,663	29,899	N/A	31,729	N/A
12/31/2014	88,806	26,481	N/A	31,692	N/A
9/30/2014	85,919	26,005	N/A	29,763	N/A
6/30/2014	84,181	25,920	N/A	23,783	N/A
3/31/2014	83,932	25,660	N/A	22,941	N/A
12/31/2013	83,572	25,184	N/A	25,942	N/A
9/30/2013	82,836	24,886	N/A	22,084	N/A
6/30/2013	82,170	24,138	N/A	23,829	N/A
3/31/2013	80,258	22,750	N/A	23,697	N/A
12/31/2012	78,026	21,432	N/A	22,214	N/A

アナリストによる今後の成長予測

収入対貯蓄率: NOVOBの予測収益成長率 (年間15.2% ) は貯蓄率 ( 0.08% ) を上回っています。

収益対市場: NOVOBの収益 ( 15.2% ) はSwiss市場 ( 8.3% ) よりも速いペースで成長すると予測されています。

高成長収益: NOVOBの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: NOVOBの収益 ( 14.5% ) Swiss市場 ( 4.4% ) よりも速いペースで成長すると予測されています。

高い収益成長: NOVOBの収益 ( 14.5% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: NOVOBの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Novo Nordisk 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Novo Nordisk Revises Earnings Guidance for the Year 2023

Novo Nordisk A/S Provides Earnings Guidance for the Year 2023

Recent updates

Novo Nordisk A/S Announces Monlunabant Phase 2A Trial in Obesity Successfully Completed

Aragen Life Sciences Reportedly Plans to Dilute About 10% Stake

Novo Nordisk A/S Decides to Pay Interim Dividend for 2024, Payable on 19 August 2024 for A and B Shares and 26 August 2024 for ADRs

European Regulatory Authority Adopts A Positive Opinion for an Update of the Wegovy® Label to Reflect Risk Reduction of Major Adverse Cardiovascular Events

Novo Nordisk Receives Complete Response Letter in the US for Once-Weekly Basal Insulin Icodec

Novo Nordisk Announces Wegovy (Semaglutide Injection) Available in Canada

Mankind Reportedly Joins Race for Healthium Medtech

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Cardior Pharmaceuticals GmbH from EQT Life Sciences and others for €1.03 billion.

Novo Nordisk Announces Awiqli Recommends for Approval for the Treatment of Diabetes by the European Regulatory Authorities

Novo Nordisk Announces US Food and Drug Administration Approves Wegovy® Based on A Supplemental New Drug Application for the Indication of Reducing Risk of Major Dose Cardiovascular Events

Novo Nordisk A/S Proposes Final Dividend for the Year 2023

Novo Nordisk A/S (CPSE:NOVO B) announces an Equity Buyback for DKK 20,000 million worth of its shares.

Novo Nordisk A/S Announces Topline Results from the Combine 3 Phase 3A Trial of Once-Weekly IcoSema

Novo Nordisk A/S to Report First Half, 2024 Results on Aug 07, 2024

Novo Nordisk Revises Earnings Guidance for the Year 2023

Novo Nordisk to Stop the Once-Weekly Injectable Semaglutide Kidney Outcomes Trial, Flow, Based on Interim Analysis

New minor risk - Shareholder dilution

Novo Nordisk A/S (CPSE:NOVO B) acquired Embark Biotech ApS for approximately €470 million.

Now 21% undervalued

Second quarter 2023 earnings released: EPS: kr.8.65 (vs kr.5.87 in 2Q 2022)

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Inversago Pharma Inc. from Genesys Capital Partners Inc., Accel-Rx, Tarnagulla Ventures Pty. Ltd., Fonds de solidarité FTQ, adMare BioInnovations and others for $1 billion.

Novo Nordisk A/S Provides Earnings Guidance for the Year 2023

New major risk - Share price stability

Investor sentiment improves as stock rises 17%

Now 20% undervalued after recent price drop

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire a 64.4% stake in Biocorp Production (ENXTPA:ALCOR) for €99.1 million.

Novo Nordisk Enters into Exclusive Negotiations to Acquire A Controlling Stake in Bicorp, to Be Followed by A Tender Offer on All Remaining Shares

Novo Nordisk A/S Announces Headline Results from OASIS 1

First quarter 2023 earnings released: EPS: kr.8.81 (vs kr.6.24 in 1Q 2022)

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘